← Leaderboards
Marian W Fischman
Columbia University Health Sciences
$5,515,675
Attributed
$5,515,675
Total exposure
13
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$6,559,877 · 14
By mechanism
M01$2,557,256 · 8
R01$1,692,632 · 3
P50$1,671,800 · 2
U19$638,189 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Denise B Kandel$14,719,404
- Sabina Hirshfield$4,641,038
- Jan Claassen$3,984,991
- Frances Rudnick Levin$39,078,718
- Edward V Nunes$88,947,598
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Abuse ChemotherapyCocaineDrug AbuseDrug AddictionDrug InteractionsSelf MedicationDrug Screening /EvaluationDrug Addiction AntagonistReinforcerModel Design /DevelopmentIntravenous Drug AbuseSubstance Abuse Related BehaviorDisease /Disorder ModelDopamine ReceptorQuestionnairesSerotonin InhibitorDextromethorphanPsychopharmacologyBehavioral /Social Science Research TagAlcoholism /Alcohol AbuseOpiate Alkaloid
Grant awards (43)
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$192,910
M01 · FY2002 · RR
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS$192,910
M01 · FY2002 · RR
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR$192,910
M01 · FY2002 · RR
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE$192,910
M01 · FY2002 · RR
AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE$192,910
M01 · FY2002 · RR
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS$192,910
M01 · FY2002 · RR
USE OF A LABORATORY MODEL WITH HUMAN SUBJECTS$171,205
U19 · FY2002 · DA
LABORATORY MODEL FOR HEROIN ABUSE MEDICATIONS$0
P50 · FY2002 · DA
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE$192,910
M01 · FY2001 · RR
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS$192,910
M01 · FY2001 · RR
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$192,910
M01 · FY2001 · RR
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR$192,910
M01 · FY2001 · RR
AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE$192,910
M01 · FY2001 · RR
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS$192,910
M01 · FY2001 · RR
AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE$0
M01 · FY2001 · RR
LABORATORY MODEL FOR HEROIN ABUSE MEDICATIONS$0
P50 · FY2001 · DA
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR$0
M01 · FY2001 · RR
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE$0
M01 · FY2001 · RR
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2001 · RR
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2001 · RR
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$0
M01 · FY2001 · RR
NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE$1,044,202
P50 · FY2000 · DA
DRUG EFFECTS ON BEHAVIOR--WORKPLACE IMPLICATIONS$614,988
R01 · FY2000 · DA
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$563,624
R01 · FY2000 · DA
NOVEL COCAINE PHARMACOTHERAPIES: LAB STUDIES$514,020
R01 · FY2000 · DA
LABORATORY MODEL FOR HEROIN ABUSE MEDICATIONS$313,799
P50 · FY2000 · DA
LABORATORY MODEL FOR HEROIN ABUSE MEDICATIONS$313,799
P50 · FY2000 · DA
USE OF A LABORATORY MODEL WITH HUMAN SUBJECTS$295,779
U19 · FY2000 · DA
USE OF A LABORATORY MODEL WITH HUMAN SUBJECTS$171,205
U19 · FY2000 · DA
EFFECTS OF DEXAMETHASONE ON NEUROENDOCRINE EFFECTS OF COCAINE$121,168
M01 · FY2000 · RR
ADHD IMAGING$121,168
M01 · FY2000 · RR
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2000 · RR
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$0
M01 · FY2000 · RR
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$0
M01 · FY2000 · RR
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR$0
M01 · FY2000 · RR
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR$0
M01 · FY2000 · RR
AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE$0
M01 · FY2000 · RR
AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE$0
M01 · FY2000 · RR
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE$0
M01 · FY2000 · RR
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE$0
M01 · FY2000 · RR
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2000 · RR
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2000 · RR
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS$0
M01 · FY2000 · RR